Outcome of Allogeneic Hematopoietic Stem Cell Transplantation

Recruiting

• Conditions: Hematopoietic Stem Cell Transplant (HSCT)

• Registration Number: NCT06702111
• Lead Sponsor: The University of Hong Kong

Brief Summary

To collect baseline and outcome data relating to all bone marrow, peripheral blood, cord blood hematopoietic stem cell transplants and therapies related to hematopoietic stem cell transplantation performed in Queen Mary Hospital.

Detailed Description

Not available

Study Timeline

• Status Verified: 2024-11
• Study First Submitted: 2024-11-20
• Study First Submitted QC: 2024-11-20
• Study First Posted: 2024-11-22
• Last Update Submitted: 2024-11-25
• Last Update Posted: 2024-11-27
• Study Start: 2024-12
• Primary Completion: 2029-12
• Study Completion: 2030-12

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 1000

Inclusion Criteria

• Adult patients aged 18 years or older who received allogeneic hematopoietic stem cell transplantation (allo-HSCT).

Exclusion Criteria

• participant who is unable to give informed consent in a prospective cohort.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Overall survival	5 year	Time from HSCT to death or latest follow-up
Relapse-free survival	5 years	Time from HSCT to relapse, death or latest follow-up

Trial Locations

Locations (2)

Department of Medicine, Queen Mary Hospital; 🇭🇰 Hong Kong, Hong Kong

Queen Mary Hospital, Hong Kong; 🇭🇰 Hong Kong, Hong Kong